Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer
Cannabis Law Report
JUNE 25, 2021
Nutt Will Drive Progression of a Pipeline of New Psychedelic Medicines, Helping to Define a Clear Development Pathway to Treat Addiction Through Psychedelic Medicines. David Nutt, has joined its executive team as Chief Research Officer. Toronto, Ontario–(Newsfile Corp. June 24, 2021) – Awakn Life Sciences Corp.
Let's personalize your content